ERBB2 and breast carcinoma: Adjuvant endocrine therapy is an effective strategy against estrogen receptor-positive and other related types of breast cancer, such as luminal A, luminal B, or HER2+ (Schiavon and Smith, 2014; Burstein et al., 2019).